Structure-guided design of N-phenyl tertiary amines as transrepression- selective liver X receptor modulators with anti-inflammatory activity

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5758-5765

  Chao, Esther Y ^a   Caravella, Justin A ^c   Watson, Mike A ^c   Campobasso, Nino ^a   Ghisletti, Serena ^b   Billin, Andrew N ^a   Galardi, Cristin ^a   Wang, Ping ^a   Laffitte, Bryan A ^c   Iannone, Marie A ^a   Goodwin, Bryan J ^a   Nichols, Jason A ^a   Parks, Derek J ^a   Stewart, Eugene ^a   Wiethe, Robert W ^a   Williams, Shawn P ^a   Smallwood, Angela ^a   Pearce, Kenneth H ^a   Glass, Christopher K ^b   Willson, Timothy M ^a   Zuercher, William J ^a   Collins, Jon L ^a,c   more..

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [BUTYL [[3 CHLORO 4,5 BIS(METHYLOXY)PHENYL]METHYL]AMINO]PHENYL] 1,1,1,3,3,3 HEXAFLUORO 2 PROPANOL; 4 [[BUTYL [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHYL)ETHYL]PHENYL]AMINO]METHYL] 2,6 DICHLOROPHENOL; GSK 9772; LIGAND; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR BETA; N PHENYL TERTIARY AMINE DERIVATIVE; T 1317; TERTIARY AMINE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL LINE; CRYSTAL STRUCTURE; CULTURE MEDIUM; DRUG DESIGN; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE EXPRESSION REGULATION; GENE REPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; LIPOGENESIS; LIVER CELL; MACROPHAGE; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; TRANSACTIVATION; WESTERN BLOTTING;

AMINES; ANTI-INFLAMMATORY AGENTS; CRYSTALLOGRAPHY, X-RAY; DNA-BINDING PROTEINS; DRUG DESIGN; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 52449127472     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800612u     Document Type: Article

References (22)

1. (a) Lehmann, J. M.; Kliewer, S. A.; Moore, L. B.; Smith-Oliver, T. A.; Blanchard, D. E.; Spencer, T. A.; Willson, T. M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 1997, 272, 3137-3140.
2. Spencer, T. A.; Gayen, A. K.; Phirwa, S.; Nelson, J. A.; Taylor, F. R.; Kandutsch, A. A.; Erickson, S. K. 24(S),25-Epoxycholesterol. Evidence consistent with a role in the regulation of hepatic cholesterogenesis. J. Biol. Chem. 1985, 260, 13391-13394.
3. Collins, J. L.; Fivush, A. M.; Watson, M. A.; Galardi, C. M.; Lewis, M. C.; Moore, L. B.; Parks, D. J.; Wilson, J. G.; Tippin, T. K.; Binz, J. G.; Plunket, K. D.; Morgan, D. G.; Beaudet, E. J.; Whitney, K. D.; Kliewer, S. A.; Willson, T. M. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 2002, 45, 1963-1966.
4. Schultz, J. R.; Tu, H.; Luk, A.; Repa, J. J.; Medina, J. C.; Li, L.; Schwendner, S.; Wang, S.; Thoolen, M.; Mangelsdorf, D. J.; Lustig, K. D.; Shan, B. Role of LXRs in control of lipogenesis. Genes Dev. 2000, 14, 2831-2838.
5. Rader, D. J. Liver X receptor and farnesoid X receptor as therapeutic targets. Am. J. Cardiol 2007, 100, 15N-19N.
6. Zelcer, N.; Tontonoz, P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 2006, 116, 607-614.
7. Collins, J. L. Therapeutic opportunities for liver X receptor modulators. Curr. Opin. Drug Discov. Devel. 2004, 7, 692-702.
8. (a) Jaye, M. LXR agonists for the treatment of atherosclerosis. Curr. Opin. Invest. Drugs 2003, 4, 1053-1058.
9. (b) Lund, E. G.; Menke, J. G.; Sparrow, C. P. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler., Thromb., Vasc. Biol. 2003, 237, 1169-1177.
10. Groot, P. H. E.; Pearce, N. J.; Yates, J. W.; Stocker, C.; Sauermelch, C.; Doe, C. P.; Willette, R. N.; Olzinski, A.; Peters. T.; d'Epagnier, D.; Morasco, O.; Krawiec, J. A.; Webb, C. L.; Aravindhan, K.; Jucker, B.; Burgert, M.; Ma, C.; Marino, J. P.; Collins, J. L.; Macphee, C. H.; Thompson, S. K.; Jaye, M. Synthetic LXR agonists increase LDL in CETP species. J. Lipid Res. 2005, 46, 2182-2191.
11. Williams, S.; Bledsoe, R. K.; Collins, J. L.; Boggs, S.; Lambert, M. H.; Miller, A. B.; Moore, J.; McKee, D. D.; Moore, L.; Nichols, J.; Parks, D.; Watson, M.; Wisely, B.; Willson, T. M. X-ray crystal structure of the liver X receptor β ligand binding domain: regulation by a histidine-tryptophan switch. J. Biol. Chem. 2003, 278, 27138-27143.
12. Masciadri, R.; Kamer; Matthias, N. N regioselective Friedel-Crafts alkylation of anilines and amino-substituted heteroarenes with hexafluoroacetone sesquihydrate. Eur. J. Org. Chem. 2003, 21, 4286-4291.
13. Resche-Rigon, M.; Gronemeyer, H. Therapeutic potential of selective modulators of nuclear receptor action. Curr. Opin. Chem. Biol. 1998, 2, 501-507.
14. de Lera, A. R.; Bourguet, W.; Altucci, L.; Gronemeyer, H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat. Rev. Drug Discovery 2007, 6, 811-820.
15. Jaye, M.; Krawiec, J. A.; Campobasso, N.; Smallwood, A.; Qiu, C.; Lu, Q.; Kerrigan, J. J.; De Los Frailes Alvaro, M.; Laffitte, B.; Liu, W.-S.; Marino, J. P., Jr.; Meyer, C. R.; Nichols, J. A.; Parks, D. J.; Perez, P.; Sarov-Blat, L.; Seepersaud, S. D.; Steplewski, K. M.; Thompson, S. K.; Wang, P.; Watson, M. A.; Webb, C. L.; Haigh, D.; Caravella, J. A.; Macphee, C. H.; Willson, T. M.; Collins, J. L. Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure. J. Med. Chem. 2005, 48, 5419-5422.
16. Iannone, M. A.; Consler, T. G.; Pearce, K. H.; Stimmel, J. B.; Parks, D. J.; Gray, J. G. Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres. Cytometry 2001, 44, 326-337.
17. Iannone, M. A.; Simmons, C. A.; Kadwell, S. H.; Svoboda, D. L.; Vanderwall, D. E.; Deng, S.-J.; Consler, T. G.; Shearin, J.; Gray, J. G.; Pearce, K. H. Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Mol. Endocrinol. 2004, 18, 1064-1081.
18. Ghisletti, S.; Huang, W.; Ogawa, S.; Pascual, G.; Lin, M.-E.; Willson, T. M.; Rosenfeld, M. G.; Glass, C. K. Parallel SUMOy-lation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ. Mol. Cell 2007, 25, 57-70.
19. Treuter, E.; Gustafsson, J.-A. Wrestling rules in transrepression: as easy as SUMO-1, -2, -3. Mol. Cell 2007, 25, 178-180.
20. Trump, R. P.; Cobb, J. E.; Shearer, B. G.; Lambert, M. H.; Nolte, R. T.; Willson, T. M.; Buckholz, R. G.; Zhao, S. M.; Leesnitzer, L. M.; Iannone, M. A.; Pearce, K. H.; Billin, A. N.; Hoekstra, W. J. Co-crystal structure guided array synthesis of PPARγ inverse agonists. Bioorg. Med. Chem. Lett. 2007, 17, 3916-3920.
21. Spencer, T. A.; Li, D.; Russel, J. S.; Collins, J. L.; Bledsoe, R. K.; Consler, T. G.; Moore, L. B.; Galardi, C. M.; McKee, D. D.; Moore, J. T.; Watson, M. A.; Parks, D. J.; Lambert, M. H.; Willson, T. M. Pharmacophore analysis of the nuclear oxysterol receptor LXRα. J. Med. Chem. 2001, 44, 886-897.
22. Noble, S. M.; Carnahan, V. E.; Moore, L. B.; Luntz, T.; Wang, H.; Ittoop, O. R.; Stimmel, J. B.; Davis-Searles, P. R.; Watkins, R. E.; Wisely, G. B.; LeCluyse, E.; Tripathy, A.; McDonnell, D. P.; Redinbo, M. R. Human PXR forms a tryptophan zipper-mediated homodimer. Biochemistry 2006, 45, 8579-8589.